| 货号 | 产品名称 | 规格 | 库存 | 价格 | 数量 | 购买 |
|---|---|---|---|---|---|---|
| KR0057 | TNF-α/ TNFA/ TNFSF2, Human, Recombinant | 10ug |
+
-
|
|
| 分子量 | 16.9 kDa |
|---|---|
| 表观分子量 | 15-17 kDa |
| 生物活性 | Measured in a cytotoxicity assay using L‑929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is typically 0.3 ng/ mL. |
| 物种 | Human |
| 表达宿主 | E.coli |
产品特性
| 纯度 | ＞95% as determined by reducing SDS-PAGE. |
|---|---|
| 内毒素 | ＜1.0 EU per µg as determined by LAL test. |
| 保存 | Lyophilized Protein should be stored at ＜ -20℃, though stable at room temperature for 3 weeks.Reconstituted Protein solution can be stored at 4-7℃ for 2-7 days.Aliquots of reconstituted samples are stable at ＜ -20℃ for 3 months |
产品介绍
Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF Receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.
